N/A N=20 Randomized Triple-blind Treatment

Exposure, D-cycloserine Enhancement, and Functional Magnetic Resonance Imaging (fMRI) in Snake Phobics

Specific Phobia

Bottom Line

View on ClinicalTrials.gov: NCT01450306 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Apr 2016

Primary outcome: Primary: Snake Questionnaire (SNAQ) — 9.6; 9.7 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: D-cycloserine (Drug); Exposure therapy (Behavioral); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Hartford Hospital
Primary completion: Dec 2011

Outcome Measures

Outcome	Result	p-value
PRIMARY Snake Questionnaire (SNAQ)	9.6; 9.7	—
SECONDARY Clinician's Global Impression (CGI)-Severity	3; 2.7	—
SECONDARY Clinician's Global Impression (CGI)-Improvement	8; 9	—

Summary

The aim of the present study is to determine whether people receiving d-cycloserine and exposure therapy show different brain reactions to symptom provocation compared to people receiving placebo and exposure therapy.

Eligibility Criteria

Inclusion Criteria

Primary diagnosis of specific phobia (snakes)

Exclusion Criteria

History of psychosis, obsessive-compulsive disorder, or mania
Recent substance abuse or suicidality
Previous receipt of study treatments

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01450306). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.